BTK inhibition to prevent hyperinflammatory syndrome in COVID-19 patients
- Funded by Netherlands Organisation for Health Research and Development (ZonMW)
- Total publications:0 publications
Grant number: 1.043E+13
Grant search
Key facts
Disease
COVID-19Start & end year
20202020Known Financial Commitments (USD)
$431,957.2Funder
Netherlands Organisation for Health Research and Development (ZonMW)Principal Investigator
PendingResearch Location
NetherlandsLead Research Institution
Erasmus Medical CenterResearch Priority Alignment
N/A
Research Category
Therapeutics research, development and implementation
Research Subcategory
Pre-clinical studies
Special Interest Tags
N/A
Study Type
Clinical
Clinical Trial Details
Unspecified
Broad Policy Alignment
Pending
Age Group
Unspecified
Vulnerable Population
Unspecified
Occupations of Interest
Unspecified
Abstract
Project description About 5% of all COVID-19 patients become seriously ill and must be admitted to intensive care. This patient group often develops serious damage to organs and has a high risk of death. This is because certain cells of the immune system, especially the monocytes, overreact to the virus. This is also called a hyper-inflammatory syndrome. The protein Bruton's tyrosine kinase (BTK) is involved, among other things, in monocyte activation and can be inhibited by the specific BTK inhibitor acalabrutinib. Other cells that are very important for killing the virus, such as T cells, are not affected by BTK inhibitors. Research and expected outcome This study will investigate whether acalabrutinib treatment indeed leads to clinical improvement in admitted COVID-19 patients. In addition, the effects of acalabrutinib on the various cells of the immune system are identified in order to gain knowledge about the mode of action of acalabrutinib in COVID-19 patients.